MedTrace Logo

Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine

NCT01758185 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3308

Last updated 2013-03-28

No results posted yet for this study

Summary

The objective of this study was to evaluate the safety and immunogenicity of one inactivated split influenza vaccine, a primarily Chinese-marketed trivalent vaccine.

Conditions

  • Healthy

Interventions

BIOLOGICAL

recombinant hepatitis b vaccine

0.5ml intramuscular

BIOLOGICAL

Aleph influenza vaccine

0.5ml intramuscular

Sponsors & Collaborators

  • Beijing Center for Disease Control and Prevention

    lead OTHER_GOV

Principal Investigators

  • Nianmin Shi, Master · Beijing Chaoyang District Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2011-11-30
Completion
2012-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01758185 on ClinicalTrials.gov